EMEM

Virtus Glovista Emerging Markets ETF

Up$23.58
+$0.05
(+0.21%)
As of 8:32:48 PM EDT | 1/24/20  |  Market Closed

EMEM Trading Data

Open

$23.52

Low Price

$23.49

High Price

$23.58

Previous Last Price

$23.53

Bid Size

$ X

Ask Size

$ X

EMEM Portfolio Data

AUM

$2,374,000

Shares

100

PE Ratio

12.64

Price / Book Ratio

1.48

Expense Ratio

0.67

Net Asset Value

$23.74

Volume

Volume

1,300

Avg. Volume (YDT)

11,075

Dollar Volume

$11,784

Weekly Avg. Volume

1,020

Monthly Avg. Volume

9,010

Quarterly Avg. Volume

3,453

EMEM Fund Description

The Virtus Glovista Emerging Markets ETF seeks to provide passive, diversified exposure to stocks in most favored emerging markets countries while avoiding exposure to those from a set of the weakest countries, as identified by Glovistas proprietary quantitative methodology.

EMEM Chart

EMEM Summary

Fund Family

Virtus ETF Advisors LLC

Tracks This Index

Virtus Glovista Emerging Markets ETF

Inception Date

2017-11-07

Asset Class

Equity

Asset Class Size

EMEM Classification

Region (General)

Emerging-Broad

Region (Specific)

Sector

Equity Index

Leveraged Family

EMEM Holdings

Top 10 Holdings

Cash/Cash equivalents
753.43%
Virtus Glovista Emerging Markets ETF (EMEM)
0%
Celltrion Healthcare Co Ltd (091990 KS)
0%
Celltrion Inc (068270 KS)
0%
%
%
%
%
%
%

Total EMEM Holdings

Total Holdings: 4

Cash/Cash equivalents
753.43%
Virtus Glovista Emerging Markets ETF (EMEM)
0%
Celltrion Healthcare Co Ltd (091990 KS)
0%
Celltrion Inc (068270 KS)
0%

EMEM Technicals

Alpha

0

Beta

0.71

Leverage

Long

Standard Deviation

0.61

EMEM Dividends

Dividend Date

2019-12-20

Latest Dividend

0.067

Annual Dividend

0.07

Annual Dividend Rate

0.07

Annual Dividend Yield

0.28

EMEM Performance

YTD Return

1.44%

1 Year Return

4.94%

3 Year Return

0%

5 Year Return

0%

10 Year Return

-5.07%

EMEM Related Articles

© 2020 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions.

Fundamental company data provided by Morningstar and Zacks Investment Research. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.